SavedAdd your journal

Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 3

Multipl miyelomda akım sitometrinin rolü ve CD87 (uPAR) ekspresyonunun prognostik önemi

Role of flow cytometry in multiple myeloma and the prognostic significance of CD87 (uPAR) expression

Murat ALBAYRAK
Özlem Şahin BALÇIK
Simten DAĞDAŞ
Mesude YILMAZ
Funda CERAN
Osman YOKUŞ
GÜLSÜM ÖZET
Pages
182–189
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further clinical studies including large numbers of patients are needed to determine the prognostic role of CD87 in MM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The plasminogen activator system consists of the serine protease urokinase plasminogen activator (uPA), two endogenous inhibitors of PAI-1 (plasminogen activator inhibitor-1) as well as the PAI-2 and uPA receptor (uPAR or CD87).
📊
Key Findings & Data:The aim of this study was to determine the significance of flow cytometry and CD87, CD45 and CD56 expressions in the diagnosis, follow-up and prognosis of multiple myeloma (MM).
💡
Conclusion & Impact:Further clinical studies including large numbers of patients are needed to determine the prognostic role of CD87 in MM.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The plasminogen activator system consists of the serine protease urokinase plasminogen activator (uPA), two endogenous inhibitors of PAI-1 (plasminogen activator inhibitor-1) as well as the PAI-2 and uPA receptor (uPAR or CD87). The aim of this study was to determine the significance of flow cytometry and CD87, CD45 and CD56 expressions in the diagnosis, follow-up and prognosis of multiple myeloma (MM). Materials and Methods: Twenty-nine MM patients were included in the study. Bone marrow samples were used for flow cytometry. A panel of CD87, CD45, CD56, CD10, CD19, CD20, CD38, and CD138 was tested by flow cytometry. Results: CD87 was negative in 8 (27.5%) cases, dim positive in 9 (31.1%) and bright positive in 12 (41.4%). CD87 expression was significantly higher in CD45 (-) cases. Conclusion: Flow cytometry has a significant role in the diagnosis and prognosis of MM. Further clinical studies including large numbers of patients are needed to determine the prognostic role of CD87 in MM.

Özet

Amaç: Plazminojen aktivatör sistemi; serin proteaz ürokinaz plazminojen aktivatörü (uPA), iki endojen inhibitörü PAI-1 (plazminojen aktivatör inhibitör-1) ve PAI-2 ile uPA reseptöründen (uPAR veya CD87) oluşmaktadır. Bu çalışmada MM tanı, takip ve prognozunda akım sitometri metodunun ve CD87, CD45, CD56 ekspresyonunun önemini belirlemek amaçlanmıştır. Yöntem ve Gereçler: Çalışmaya 29 MM hastası alındı. Akım sitometri için kemik iliği örneği kullanıldı. Hastalara akım sitometri yöntemi ile CD87, CD45, CD56, CD10, CD19, CD20, CD38, CD138’i içeren panel çalışıldı. Bulgular: Çalışmamızda CD87; 8 (% 27.5) olguda negatif, 9 (% 31.1) olguda zayıf pozitif, 12 (% 41.4) olguda ise kuvvetli pozitif bulundu. CD 45 (-) olgularda CD 87 ekspresyonu anlamlı olarak yüksek bulundu. Sonuç: Akım sitometri MM tanısı ve prognozu belirlemede önemli role sahiptir. MM’da CD87 ekspresyonunun prognostik rolünü belirlemek için çok sayıda hasta içeren daha fazla klinik çalışmaya ihtiyaç vardır.

🔖

Cite This Article

ALBAYRAK, M., BALÇIK, Ö. Ş., DAĞDAŞ, S., YILMAZ, M., CERAN, F., YOKUŞ, O., ÖZET, G. (2010). Multipl miyelomda akım sitometrinin rolü ve CD87 (uPAR) ekspresyonunun prognostik önemi. Turkish Journal of Hematology, Cilt: 27 - Sayı: 3, 182–189. https://ajindex.com/articles/413172

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. 1 Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology Basic Principles and Practice. 4th ed. Philadelphia: Elsevier Science, 2005:1501-21. 2 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003
  2. 3 Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005
  3. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE
  4. European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008
  5. Epub 2008 Feb 11. 5. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004
  6. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood 1994
  7. Béné MC, Castoldi G, Knapp W, Rigolin GM, Escribano L, Lemez P, Ludwig WD, Matutes E, Orfao A, Lanza F, van't Veer M
  8. EGIL, European Group on Immunological Classification of Leukemias. CD 87 (Urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 2004
  9. Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A, Börset M. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 2000
  10. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M. Expression of CD 28 and CD 40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994
  11. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Adhesion molecules o